---
title: "SYNGAP1"
date: 2023-05-16 00:00:00
layout: post
categories: Gene
summary: "## Gene: SYNGAP1"
tags: ['SYNGAP1', 'NeurologicalDisorders', 'CognitiveDisorders', 'SynapticFunction', 'IntellectualDisability', 'Epilepsy', 'Autism', 'Schizophrenia']
---

## Gene: SYNGAP1

### Genetic Position
The SYNGAP1 gene is located on the short arm of chromosome 6 at the position 21.3.

### Pathology
Mutations in SYNGAP1 have been associated with various neurological and cognitive disorders, including intellectual disability, epilepsy, autism, schizophrenia, and Parkinson's disease. 

### Function
The SYNGAP1 gene encodes the protein SynGAP, which is primarily expressed in the brain and plays a crucial role in regulating synaptic function and plasticity. SynGAP acts as a GTPase-activating protein (GAP) for the small G protein Ras, which is involved in several signaling pathways that regulate synaptic plasticity, learning, and memory. 

### External IDs and Aliases
- HGNC: 11411
- NCBI Entrez: 8831
- Ensembl: ENSG00000134057
- OMIM: 603384
- UniProtKB/Swiss-Prot: Q96PV0
- Aliases: MRD5, RASA5, SYNGAP

### AA Mutation List and Mutation Type with dbSNP ID
Several missense mutations have been reported in the SYNGAP1 gene, including:
- R62Q (rs375042685)
- R579X (rs267608594)
- V87E (rs376751599)
- A113T (rs761317896)
- T512M (rs121908325)
- E130K (rs797001838)
- R1023Q (rs387906799)

### Somatic SNVs/InDels with dbSNP ID
No significant somatic SNVs/InDels have been reported for SYNGAP1 in various cancer types.

### Related Disease
Mutations in SYNGAP1 have been associated with several neurological and cognitive disorders, including:
- Intellectual disability (ID) and developmental delay
- Epilepsy, including generalized and focal seizures
- Autism spectrum disorders (ASD)
- Schizophrenia and other psychiatric disorders
- Parkinson's disease and other movement disorders

### Treatment and Prognosis
Currently, there is no cure for SYNGAP1-related disorders, and treatment options are mostly supportive and symptomatic. Treatment may include anticonvulsants, behavioral and educational interventions, and physical and occupational therapy. 

The prognosis of SYNGAP1-related disorders varies depending on the severity and type of symptoms and the age of onset. Some patients may experience mild to moderate intellectual disability or seizures, while others may have severe developmental delays, refractory epilepsy, and movement disorders.

### Drug Response
Several pharmacological agents that target synaptic function and plasticity are being investigated as potential treatments for SYNGAP1-related disorders, including drugs that enhance N-methyl-D-aspartate (NMDA) receptor function or modulate G protein-coupled receptor (GPCR) signaling.

### Related Papers
- Hamdan, F.F., Gauthier, J., Spiegelman, D., Noreau, A., Yang, Y., Pellerin, S., ... & Michaud, J.L. (2009). Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation. New England Journal of Medicine, 360(6), 599-605.
- Berryer, M.H., Hamdan, F.F., Klitten, L.L., Møller, R.S., Carmant, L., Schwartzentruber, J., ... & Mercimek-Mahmutoglu, S. (2013). Mutations in SYNGAP1 cause intellectual disability, autism, and a specific form of epilepsy by inducing haploinsufficiency. Human Mutation, 34(2), 385-394.
- Clement, J.P., Ozkan, E.D., Aceti, M., Miller, C.A., Rumbaugh, G., & Sudhof, T.C. (2013). Selective small‐molecule inhibitors of the phosphatase activity of striatal-enriched protein tyrosine phosphatase (STEP). Proceedings of the National Academy of Sciences, 110(49), E4888-E4897.

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**